- Home
- INBX vs DSGN Comparison
INBX vs DSGN Comparison
Compare INBX & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- DSGN
- Stock Information
- Founded
- INBX 2010
- DSGN 2017
- Country
- INBX United States
- DSGN United States
- Employees
- INBX N/A
- DSGN N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- INBX Health Care
- DSGN Health Care
- Exchange
- INBX Nasdaq
- DSGN Nasdaq
- Market Cap
- INBX 430.2M
- DSGN 418.1M
- IPO Year
- INBX 2020
- DSGN 2021
- Fundamental
- Price
- INBX $83.93
- DSGN $8.21
- Analyst Decision
- INBX Hold
- DSGN Buy
- Analyst Count
- INBX 2
- DSGN 1
- Target Price
- INBX N/A
- DSGN $13.00
- AVG Volume (30 Days)
- INBX 458.6K
- DSGN 437.5K
- Earning Date
- INBX 11-14-2025
- DSGN 11-05-2025
- Dividend Yield
- INBX N/A
- DSGN N/A
- EPS Growth
- INBX N/A
- DSGN N/A
- EPS
- INBX N/A
- DSGN N/A
- Revenue
- INBX $1,400,000.00
- DSGN N/A
- Revenue This Year
- INBX $563.00
- DSGN N/A
- Revenue Next Year
- INBX $230.77
- DSGN N/A
- P/E Ratio
- INBX N/A
- DSGN N/A
- Revenue Growth
- INBX N/A
- DSGN N/A
- 52 Week Low
- INBX $10.81
- DSGN $2.60
- 52 Week High
- INBX $86.64
- DSGN $8.80
- Technical
- Relative Strength Index (RSI)
- INBX 71.64
- DSGN 66.80
- Support Level
- INBX $79.05
- DSGN $7.25
- Resistance Level
- INBX $85.75
- DSGN $8.80
- Average True Range (ATR)
- INBX 6.92
- DSGN 0.68
- MACD
- INBX -0.97
- DSGN 0.10
- Stochastic Oscillator
- INBX 81.14
- DSGN 86.38
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.